Mechanisms of Disease:: β-adrenergic receptors -: alterations in signal transduction and pharmacogenomics in heart failure

被引:92
作者
Feldman, DS
Carnes, CA
Abraham, WT
Bristow, MR
机构
[1] Ohio State Univ, Div Cardiol Med, Davis Heart & Lung Res Inst, Columbus, OH 43210 USA
[2] Univ Colorado, Hlth Sci Ctr, Denver, CO 80202 USA
来源
NATURE CLINICAL PRACTICE CARDIOVASCULAR MEDICINE | 2005年 / 2卷 / 09期
关键词
beta-adrenergic receptor; gene polymorphism; heart failure; pharmacogenomics; signal transduction;
D O I
10.1038/ncpcardio0309
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
beta-adrenergic signaling is an important regulator of myocardial function. During the progression of heart failure (HF), a reproducible series of biochemical events occurs that affects beta-adrenergic receptor (beta-AR) signaling and cardiac function. Furthermore, there are pathophysiologic alterations in the expression and regulation of proteins that are regulated by beta-ARs during HE Analyses of these complex signaling pathways have led to a better understanding of HF mechanisms and the use of beta-adrenergic antagonists, which have notably altered HF-related morbidity and mortality. Despite therapeutic advances that have affected beta-AR signaling, HF remains a leading cause of hospitalization and a principal cause of death in industrialized nations. In this review, we summarize current insights into beta-adrenergic signal-transduction pathways, the best-described beta-AR polymorphisms, and therapies that target the beta-AR pathway in HF.
引用
收藏
页码:475 / 483
页数:9
相关论文
共 65 条
[1]   Coordinate changes in myosin heavy chain isoform gene expression are selectively associated with alterations in dilated cardiomyopathy phenotype [J].
Abraham, WT ;
Gilbert, EM ;
Lowes, BD ;
Minobe, WA ;
Larrabee, P ;
Roden, RL ;
Dutcher, D ;
Sederberg, J ;
Lindenfeld, JA ;
Wolfel, EE ;
Shakar, SF ;
Ferguson, D ;
Volkman, K ;
Linseman, JV ;
Quaife, RA ;
Robertson, AD ;
Bristow, MR .
MOLECULAR MEDICINE, 2002, 8 (11) :750-760
[2]   G-proteins in growth and apoptosis: lessons from the heart [J].
Adams, JW ;
Brown, JH .
ONCOGENE, 2001, 20 (13) :1626-1634
[3]   Cardiac resynchronization therapy for advanced heart failure [J].
Philip B. Adamson ;
William T. Abraham .
Current Treatment Options in Cardiovascular Medicine, 2003, 5 (4) :301-309
[4]  
*AM HEART ASS HEAR, UPDATE
[5]   Cardiac HCN channels: Structure, function, and modulation [J].
Biel, M ;
Schneider, A ;
Wahl, C .
TRENDS IN CARDIOVASCULAR MEDICINE, 2002, 12 (05) :206-213
[6]   A novel polymorphism in the gene coding for the beta1-adrenergic receptor associated with survival in patients with heart failure [J].
Börjesson, M ;
Magnusson, Y ;
Hjalmarson, Å ;
Andersson, B .
EUROPEAN HEART JOURNAL, 2000, 21 (22) :1853-1858
[7]   β-adrenergic receptor blockade in chronic heart failure [J].
Bristow, MR .
CIRCULATION, 2000, 101 (05) :558-569
[8]   Effect of baseline or changes in adrenergic activity on clinical outcomes in the β-blocker evaluation of survival trial [J].
Bristow, MR ;
Krause-Steinrauf, H ;
Nuzzo, R ;
Liang, CS ;
Lindenfeld, J ;
Lowes, BD ;
Hattler, B ;
Abraham, WT ;
Olson, L ;
Krueger, S ;
Thaneemit-Chen, S ;
Hare, JM ;
Loeb, HS ;
Domanski, MJ ;
Eichhorn, EJ ;
Zelis, R ;
Lavori, P .
CIRCULATION, 2004, 110 (11) :1437-1442
[9]   Selective versus nonselective β-blockade for heart failure therapy:: Are there lessons to be learned from the COMET trial? [J].
Bristow, MR ;
Feldman, AM ;
Adams, KF ;
Goldstein, S .
JOURNAL OF CARDIAC FAILURE, 2003, 9 (06) :444-453
[10]   Inotropes and β-blockers:: Is there a need for new guidelines? [J].
Bristow, MR ;
Shakar, SF ;
Linseman, JV ;
Lowes, BD .
JOURNAL OF CARDIAC FAILURE, 2001, 7 (02) :8-12